Overview

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-28
Target enrollment:
Participant gender:
Summary
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)
Phase:
PHASE1
Details
Lead Sponsor:
Zai Lab (Shanghai) Co., Ltd.